STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 61 filers reported holding STEMLINE THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $217,000 | -39.9% | 25,323 | -24.9% | 0.03% | -40.8% |
| Q4 2016 | $361,000 | -1.1% | 33,725 | 0.0% | 0.05% | -7.5% |
| Q3 2016 | $365,000 | +59.4% | 33,725 | -0.5% | 0.05% | +55.9% |
| Q2 2016 | $229,000 | +44.9% | 33,890 | 0.0% | 0.03% | +47.8% |
| Q1 2016 | $158,000 | -47.5% | 33,890 | -29.0% | 0.02% | -43.9% |
| Q4 2015 | $301,000 | -36.8% | 47,704 | -11.4% | 0.04% | -38.8% |
| Q3 2015 | $476,000 | -26.0% | 53,870 | -1.5% | 0.07% | -15.2% |
| Q2 2015 | $643,000 | +14.2% | 54,670 | +40.4% | 0.08% | +19.7% |
| Q1 2015 | $563,000 | +36.3% | 38,932 | +60.9% | 0.07% | +22.2% |
| Q4 2014 | $413,000 | +70.7% | 24,189 | +24.7% | 0.05% | +50.0% |
| Q3 2014 | $242,000 | +16.9% | 19,399 | +37.6% | 0.04% | +16.1% |
| Q2 2014 | $207,000 | -29.1% | 14,095 | -1.7% | 0.03% | -44.6% |
| Q1 2014 | $292,000 | -34.8% | 14,345 | -37.2% | 0.06% | -34.9% |
| Q4 2013 | $448,000 | – | 22,833 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
| Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
| NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
| Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
| Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
| KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
| Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
| Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
| J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |